Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgan’s 35th Annual Healthcare Conference on January 11, 2017...
December 22 2016 - 8:31AM
Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical
company focused on bringing innovative medicines to people with
renal disease, today announced it will webcast its corporate
presentation at the 35th Annual J.P. Morgan Healthcare Conference
on Wednesday, January 11 at 2:30 p.m. PST (5:30 p.m. EST).
A live audio webcast of the presentation will be
accessible from Keryx’s website at http://investors.keryx.com
within the Investor Relations section under “webcasts and
presentations.” An archived version of the webcast will be
available for at least 15 days following the conclusion of the live
presentation.
About Keryx Biopharmaceuticals,
Inc. Keryx Biopharmaceuticals, with headquarters in
Boston, is focused on bringing innovative medicines to people with
renal disease. In December 2014, the company launched its first
FDA-approved medicine, Auryxia® (ferric citrate) in the United
States. In January 2014, ferric citrate was approved for use
in Japan, where it is being marketed as Riona® by Keryx's Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In
September 2015, the European Commission granted European market
authorization for Fexeric® (ferric citrate coordination complex).
For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT:
Lora Pike
Senior Director, Investor Relations
T: 617-466-3511
lora.pike@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024